MarketSYDNEY · OCT 19 2026
NSW: 1,180 peptide-linked ER visits, most name retatrutide
Monthly visits went from five to more than 217 in 15 months. Retatrutide, a drug not approved anywhere, came up in 833 of them.
- NSW Health surveillance data: 1,180 emergency department presentations associated with peptide use between July 1, 2025 and September 30, 2026.
- Monthly presentations rose from five in July 2025 to more than 217 in September 2026, according to the Minister for Health's release.
- Retatrutide was mentioned in 833 presentations, the Newcastle Herald reported from the same data. About 18 percent ended in a hospital admission.
- NSW Health says none of the peptides it named (BPC-157, GHK-Cu, TB-500, retatrutide, CJC-1295) is approved in Australia for any purpose.